Skip to main content

OrthoPediatrics Corp. Announces Launch of Next Generation Cannulated Screw System

Written by Customer Service on . Posted in Public Companies.

WARSAW, Ind., June 10, 2021 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the launch of its 6.5mm/7.3mm Slipped Capital Femoral Epiphysis (“SCFE”) Cannulated Screw system. The company previously received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as expanded indications for its next generation Cannulated Screw System.

The OrthoPediatrics 6.5mm/7.3mm SCFE system has been completely rethought and precisely designed. The system offers flexibility to treat pediatric specific SCFE injuries with fully threaded screws and partially threaded screws for common trauma indications.

Unlike other systems on the market, the OP fully threaded SCFE screws are available in 2mm increments, providing the surgeon more options to treat pediatric populations with an implant that fits correctly instead of simply making do with what is available. The screws also incorporate useful features that can help surgeons if they choose to remove the implant. With this addition, OP now offers cannulated screws in 2.5mm, 3.0mm, 3.5mm, 4.0mm, 4.5mm, 5.5mm, 6.5mm, 7.0mm and 7.3mm sizes with various thread lengths to service almost all needs of the pediatric surgeon.

The system was designed in collaboration with pediatric orthopedic surgeons focused on more solutions for treating pediatric patients with fractures. It expands the Company’s offering to help treat the unique needs found in pediatric hospitals.

OrthoPediatrics’ Senior Vice President & General Manager, Joe Hauser, stated, “We are pleased to announce the release of our new SCFE system as part of the next generation of cannulated screws to use in specialized procedures. This continued innovation represents our continued commitment to pediatric orthopedics. Our engineering teams have been diligently working with a prominent group of surgeons, and we are excited to bring yet another system to market in our quest to meet unmet clinical needs for pediatric patients.”

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 36 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 45 countries outside the United States.

Investor Contacts
Matt Bacso, CFA
Gilmartin Group
Matt.bacso@gilmartinir.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.